Goldman Sachs Group »

Prelude Therapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Prelude Therapeutics (PRLD) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Prelude Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Prelude Therapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prelude Therapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $297k 70k 4.27
2023-09-30 $209k 68k 3.09
2023-06-30 $107k 24k 4.50
2023-03-31 $282k 50k 5.70
2022-12-31 $95k 16k 6.04
2022-06-30 $232k 44k 5.24
2022-03-31 $166k 24k 6.91
2021-12-31 $1.4M 113k 12.46
2021-09-30 $271k 8.7k 31.30
2021-03-31 $1.9M 44k 43.32
2020-09-30 $2.5M 83k 30.13